ARBUTUS BIOPHARMA
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). They believe that Arbutus' comprehensive HBV pipeline of drugs and drug candidates optimally positions us to transform the HBV treatment landscape and to capitalize on the HBV global market opportunity. They are developing a portfolio ... of drug candidates with multiple mechanisms of action that They believe will result in a combination therapy to cure HBV. Specifically, They seek to effect a cure by targeting the three pillars necessary to develop a curative regimen for HBV. This includes suppressing HBV replication within liver cells, stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence.
ARBUTUS BIOPHARMA
Industry:
Biopharma Biotechnology Genetics Health Care Medical Pharmaceutical
Founded:
1992-01-01
Address:
Burnaby, British Columbia, Canada
Country:
Canada
Website Url:
http://www.arbutusbio.com
Total Employee:
51+
Status:
Active
Contact:
(604) 419-3200
Total Funding:
354.44 M USD
Technology used in webpage:
IPv6 Pound Sterling Japanese Yen Akamai Hosted Digg
Similar Organizations
BostonGene
BostonGene is a biomedical software company for advanced patient analysis and personalized therapy in the fight against cancer.
Cassava Sciences
Cassava Sciences is a clinical-stage biopharmaceutical company focused on neuroscience.
The Grunenthal Group
The Grunenthal Group is an independent, family-owned, international research-based pharmaceutical company.
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Insmed
We are a publicly traded (NASDAQ: INSM) biopharmaceutical company dedicated to improving the lives of patients battling serious lung
Mereo Biopharma
Mereo is a new UK-based speciality biopharmaceutical company.
Mustang Bio
Mustang Bio is a clinical-stage biopharmaceutical company .
NGM Biopharmaceuticals
NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.
Opthea
Opthea Limited is a public Australian biotechnology company .
Progyny
Progyny is a fertility benefits management company.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-01-13 | OnCore Biopharma | OnCore Biopharma acquired by Arbutus Biopharma | N/A |
| 2008-03-28 | Protiva Biotherapeutics | Protiva Biotherapeutics acquired by Arbutus Biopharma | 22.8 M USD |
Investors List
Roivant Sciences
Roivant Sciences investment in Post-IPO Equity - Arbutus Biopharma
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Arbutus Biopharma
National Institutes of Health
National Institutes of Health investment in Grant - Arbutus Biopharma
BDC Venture Capital
BDC Venture Capital investment in Venture Round - Arbutus Biopharma
Key Employee Changes
| Date | New article |
|---|---|
| 2023-11-07 | Arbutus Announces CEO, William Collier, to Retire December 31, 2023 |
| 2023-07-11 | Arbutus Biopharma appoints Karen Sims as chief medical officer |
Official Site Inspections
http://www.arbutusbio.com Semrush global rank: 7.37 M Semrush visits lastest month: 803
- Host name: 226.108.198.104.bc.googleusercontent.com
- IP address: 104.198.108.226
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Arbutus Biopharma"
About Arbutus - Arbutus Biopharma : Arbutus Biopharma
About Arbutus Specialized in virology. Focused on growth. We are a clinical-stage biopharmaceutical company with deep virology expertise and an unwavering focus on curing …See details»
Leadership Team - Arbutus Biopharma
Hastings also previously served as Vice President, Chief Financial Officer and Treasurer of ArQule Inc., where he played an important role in ArQule’s transition into a drug discovery and …See details»
Arbutus Biopharma - Crunchbase Company Profile & Funding
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic …See details»
Arbutus Biopharma - Wikipedia
Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. See details»
Corporate Governance - Arbutus Biopharma Corporation
14 rows The Board of Directors of Arbutus Biopharma (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance …See details»
Arbutus Biopharma Corporation | LinkedIn
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with …See details»
Arbutus Appoints Two New Executives
Jul 10, 2023 The World Health Organization estimates that over 290 million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately 2.4 million …See details»
Arbutus Biopharma - Craft
Arbutus Biopharma has 5 employees at their 1 location and $18.14 m in annual revenue in FY 2023. See insights on Arbutus Biopharma including office locations, competitors, revenue, …See details»
Board of Directors - Arbutus Biopharma
Board Of Directors Meet our Board.. Our board of directors is made up of healthcare leaders, innovative scientists, and more. They possess deep expertise in biopharmaceuticals, healthcare, commercial and operational leadership, …See details»
Arbutus Announces 2024 Corporate Objectives and Provides …
Jan 8, 2024 The World Health Organization estimates that over 290 million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately 2.4 million …See details»
Arbutus Biopharma - Overview, News & Similar companies
May 21, 2024 Arbutus Biopharma contact info: Phone number: (267) 469-0914 Website: www.arbutusbio.com What does Arbutus Biopharma do? Founded in 1992, Arbutus …See details»
Scientific Advisory Board - Arbutus Biopharma
Dr. Di Bisceglie received his medical degree from the University of Witwatersrand, Johannesburg, South Africa in 1977 and completed his training in Internal Medicine at Baragwanath Hospital, …See details»
Arbutus Announces 2021 Corporate Objectives and Provides …
Jan 25, 2021 For more information, visit www.arbutusbio.com. Forward-Looking Statements and Information. This press release contains forward-looking statements within the meaning of the …See details»
Arbutus Biopharma Announces Issuance of a New Key U.S. Patent …
Aug 30, 2022 The World Health Organization estimates that over 290 million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately 2.4 million …See details»
Partnering - Arbutus Biopharma
To learn more, contact us at [email protected]. Our current partners include: Qilu Pharmaceutical. Arbutus and Qilu Pharmaceutical have entered into an exclusive licensing …See details»
Arbutus Reports Second Quarter 2024 Financial Results and …
Aug 1, 2024 In taking these steps to streamline the organization, Arbutus is implementing a reduction in its workforce of 40%, primarily affecting the discovery and general and …See details»
Arbutus Announces 2024 Corporate Objectives and Provides …
Jan 8, 2024 The World Health Organization estimates that over 290 million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately 2.4 million …See details»
Arbutus Announces 2024 Corporate Objectives and Provides
Jan 8, 2024 The World Health Organization estimates that over 290 million people worldwide suffer from chronic HBV infection, ... 215-206-1822 Email: [email protected] ...See details»
Arbutus Announces 2024 Corporate Objectives and Provides …
Jan 8, 2024 2024 Clinical Development Milestones. Imdusiran (AB-729, RNAi Therapeutic) AB-729-201 is a Phase 2a clinical trial that is evaluating the safety, tolerability and antiviral activity …See details»